Johnson Investment Counsel’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.03M Buy
12,976
+87
+0.7% +$13K 0.01% 341
2026
Q1
$1.97M Sell
12,889
-2,077
-14% -$318K 0.02% 330
2025
Q4
$2.06M Hold
14,966
0.02% 308
2025
Q3
$1.92M Sell
14,966
-3,740
-20% -$456K 0.02% 316
2025
Q2
$2.26M Sell
18,706
-400
-2% -$45.1K 0.02% 281
2025
Q1
$2.13M Buy
19,106
+816
+4% +$86.9K 0.02% 283
2024
Q4
$1.78M Sell
18,290
-250
-1% -$26.7K 0.02% 307
2024
Q3
$2.13M Sell
18,540
-664
-3% -$75.3K 0.02% 277
2024
Q2
$2.04M Buy
19,204
+122
+0.6% +$12.2K 0.02% 270
2024
Q1
$1.85M Buy
19,082
+387
+2% +$39.7K 0.02% 287
2023
Q4
$1.89M Buy
18,695
+1,412
+8% +$136K 0.02% 263
2023
Q3
$1.76M Buy
17,283
+1,030
+6% +$105K 0.02% 264
2023
Q2
$1.64M Buy
16,253
+37
+0.2% +$3.7K 0.02% 276
2023
Q1
$1.49M Sell
16,216
-345
-2% -$30.1K 0.02% 289
2022
Q4
$1.5M Buy
16,561
+2,865
+21% +$241K 0.02% 286
2022
Q3
$1.04M Buy
13,696
+226
+2% +$18.7K 0.02% 319
2022
Q2
$1.14M Buy
13,470
+192
+1% +$16.8K 0.02% 303
2022
Q1
$1.17M Sell
13,278
-487
-4% -$42.2K 0.01% 325
2021
Q4
$1.2M Buy
13,765
+12
+0.1% +$996 0.01% 326
2021
Q3
$1.13M Sell
13,753
-105
-0.8% -$9.45K 0.02% 326
2021
Q2
$1.26M Sell
13,858
-33
-0.2% -$2.94K 0.02% 294
2021
Q1
$1.19M Sell
13,891
-170
-1% -$15.3K 0.02% 288
2020
Q4
$1.33M Buy
14,061
+383
+3% +$33.5K 0.02% 257
2020
Q3
$1.19M Sell
13,678
-96
-0.7% -$8.32K 0.02% 253
2020
Q2
$1.2M Sell
13,774
-143
-1% -$12.3K 0.02% 242
2020
Q1
$1.15M Sell
13,917
-1,226
-8% -$109K 0.03% 225
2019
Q4
$1.43M Buy
15,143
+297
+2% +$26.6K 0.03% 242
2019
Q3
$1.29M Sell
14,846
-994
-6% -$89.2K 0.03% 251
2019
Q2
$1.45M Sell
15,840
-2,133
-12% -$181K 0.03% 245
2019
Q1
$1.55M Sell
17,973
-2,224
-11% -$179K 0.03% 235
2018
Q4
$1.55M Buy
20,197
+1,657
+9% +$129K 0.04% 222
2018
Q3
$1.43M Buy
18,540
+9
+0% +$665 0.03% 255
2018
Q2
$1.25M Sell
18,531
-4,920
-21% -$340K 0.03% 265
2018
Q1
$1.7M Sell
23,451
-465
-2% -$35.4K 0.04% 192
2017
Q4
$1.8M Buy
23,916
+1,653
+7% +$125K 0.04% 196
2017
Q3
$1.71M Sell
22,263
-30
-0.1% -$2.27K 0.05% 186
2017
Q2
$1.67M Buy
22,293
+1,947
+10% +$138K 0.05% 183
2017
Q1
$1.35M Sell
20,346
-3,991
-16% -$266K 0.04% 198
2016
Q4
$1.59M Buy
24,337
+236
+1% +$15.3K 0.05% 171
2016
Q3
$1.71M Sell
24,101
-2,638
-10% -$192K 0.05% 172
2016
Q2
$1.98M Sell
26,739
-1,144
-4% -$79K 0.07% 163
2016
Q1
$1.81M Buy
27,883
+57
+0.2% +$3.88K 0.06% 163
2015
Q4
$2.15M Buy
27,826
+1,523
+6% +$121K 0.08% 155
2015
Q3
$2.17M Buy
26,303
+1,807
+7% +$161K 0.08% 156
2015
Q2
$2.16M Buy
24,496
+898
+4% +$82.4K 0.07% 150
2015
Q1
$2.08M Buy
23,598
+983
+4% +$87.2K 0.07% 157
2014
Q4
$1.88M Buy
22,615
+3,130
+16% +$259K 0.06% 164
2014
Q3
$1.64M Buy
19,485
+9
+0% +$728 0.06% 166
2014
Q2
$1.58M Sell
19,476
-2,171
-10% -$171K 0.06% 155
2014
Q1
$1.65M Sell
21,647
-396
-2% -$28.9K 0.06% 148
2013
Q4
$1.59M Sell
22,043
-125
-0.6% -$8.69K 0.06% 152
2013
Q3
$1.52M Buy
22,168
+2,793
+14% +$185K 0.06% 151
2013
Q2
$1.23M Buy
+19,375
New +$1.26M 0.05% 159

Other funds holding NVS

Johnson Investment Counsel's NVS Position: Q2 2026 in Review

Johnson Investment Counsel increased its Novartis (NVS) stake by 0.67% in Q2 2026, buying an estimated $13K and bringing the position to 12,976 shares worth $2.03M. The position accounts for 0.01% of the portfolio, ranked #341.

Johnson Investment Counsel first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.26M in Q2 2025. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Johnson Investment Counsel held 12,976 shares of Novartis worth $2.03M as of Q2 2026.
  • Johnson Investment Counsel bought 87 Novartis shares in Q2 2026, an estimated $13K.
  • Novartis made up 0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #341 holding.
  • Johnson Investment Counsel first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Johnson Investment Counsel's Novartis position peaked at $2.26M in Q2 2025.
  • 1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.